Vaxcyte, Inc (PCVX) Prices 11.2M Share and Warrant Offering at $41/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St futures tepid as Middle East tensions keep investors wary
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Tesla to unveil Cybercab Texas today, details are few
- Snowflake soars 20% on earnings beat and raised guidance
- Oil prices hit fresh 6-week highs on renewed Middle East tensions
Vaxcyte Announces Pricing of $500 Million Public Offering
April 19, 2023 12:27 AM EDTSAN CARLOS, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public offering of common stock and pre-funded warrants. Vaxcyte is selling 11,200,000 shares of common stock and pre-funded warrants to purchase 1,000,000 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $41.00 per share, and the pre-funded warrants are being sold at a public offering price of $40.999 per... More
